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Abstract
Background
Regular use of inhaled corticosteroids (ICS) in patients with obstructive lung diseases has
been associated with a higher risk of pneumonia, particularly in COPD. The risk of pneumo-
nia has not been previously evaluated in relation to ICS particle size and dose used.
Methods
Historical cohort, UK database study of 23,013 patients with obstructive lung disease aged
12–80 years prescribed extra-fine or fine-particle ICS. The endpoints assessed during the
outcome year were diagnosis of pneumonia, acute exacerbations and acute respiratory
events in relation to ICS dose. To determine the association between ICS particle size, dose
and risk of pneumonia in unmatched and matched treatment groups, logistic and conditional
logistic regression models were used.
Results
14788 patients were stepped-up to fine-particle ICS and 8225 to extra-fine ICS. On
unmatched analysis, patients stepping-up to extra-fine ICS were significantly less likely to
be coded for pneumonia (adjusted odds ratio [aOR] 0.60; 95% CI 0.37, 0.97]); experience
acute exacerbations (adjusted risk ratio [aRR] 0.91; 95%CI 0.85, 0.97); and acute respira-
tory events (aRR 0.90; 95%CI 0.86, 0.94) compared with patients stepping-up to fine-parti-
cle ICS. Patients prescribed daily ICS doses in excess of 700 mcg (fluticasone propionate
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equivalent) had a significantly higher risk of pneumonia (OR [95%CI] 2.38 [1.17, 4.83]) com-
pared with patients prescribed lower doses, irrespective of particle size.
Conclusions
These findings suggest that patients with obstructive lung disease on extra-fine particle ICS
have a lower risk of pneumonia than those on fine-particle ICS, with those receiving higher
ICS doses being at a greater risk.
Introduction
Inhaled corticosteroids (ICS) are widely used in high doses in the management of obstructive
lung diseases such as asthma[1] and chronic obstructive pulmonary disease (COPD).[2] Cur-
rent asthma treatment guidelines recommend stepping up the ICS dose if lack of control per-
sists.[1] Alternatively, the combination of low-dose ICS with long-acting β2-agonist (LABA)
has been shown to achieve better asthma control, sparing patients higher doses of ICS.[3,4] In
patients with COPD, low-dose ICS/LABA combination has been shown to reduce exacerba-
tions, improve quality of life and lung function,[2] through an underlying complementary
anti-inflammatory cellular action.[5,6] However there continues to be significant concern
regarding inappropriate prescribing of high-dose ICS in patients with obstructive lung dis-
eases, with untoward consequences for patients.[7–9]
Indeed, regular use of ICS has been linked to several systemic effects,[10] including a higher
risk of pneumonia,[9,11–16] where it is thought that ICS exert an anti-inflammatory and
immunosuppressive effect that could affect the pathogenesis of pneumonia.[17] Most random-
ized controlled trials (RCTs),[14,15,18] observational studies[11,19,20] and meta-analysis,
[21,22] in patients with COPD suggest an increased risk of pneumonia with a dose-response
relationship between ICS and pneumonia, although there is some evidence suggesting to the
contrary.[23,24] This association is not as clear-cut in asthmatics; ICS are associated with a
decreased risk of pneumonia based on RCTs, but observational studies suggest a higher risk of
pneumonia.[25] Importantly though, all the published literature has assessed the risk of pneu-
monia only for conventional fine-particle ICS and not for extra-fine particle ICS in patients
with obstructive lung disease.
While most ICS are fine particles with a mass median aerodynamic diameter (MMAD) of
2–4 microns, some extra-fine particle ICS formulations have been produced with a particle
MMAD of 1.1 microns which improves airway deposition.[26–29] Two such ICS currently
available are extra-fine beclometasone dipropionate (efBDP) and extra-fine ciclesonide
(efCIC).[30] RCTs comparing the short-term efficacy of efBDP and efCIC to that of fine-parti-
cle ICS have found that extra-fine formulations offer equivalent efficacy when administered at
half the dose of fine-particle ICS in both asthma and COPD.[31–34] Indeed, a rigorous dose
response study has confirmed that efBDP provides significantly greater effects on lung func-
tion than comparable doses of fine-particle BDP. Of note, the improvements in obstructive
lung disease symptoms and quality of life tend to be better with efBDP than fine-particle BDP
at twice the dose,[35–40] suggesting that there may be clinically meaningful differences
between the extra-fine particle and fine-particle formulations.
We therefore aimed to compare the risk of pneumonia and other adverse respiratory conse-
quences between fine-particle ICS and extra-fine particle ICS in relation to their dose in
patients with obstructive lung disease.
Extra-fine corticosteroids and pneumonia
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Methods
Study design
A historical cohort study was conducted in patients with obstructive lung disease in the UK con-
sisting of a baseline and outcome period. The baseline period (for patient characterisation) was
the one-year prior to the index prescription date, at which point asthma or COPD patients had
their ICS therapy stepped-up (50% dose increase) as either extra-fine particle ICS (efBDP or
efCIC) or fine-particle ICS (fluticasone propionate (FP) or BDP). Budesonide was not used in
this investigation given the lack of or conflicting evidence that budesonide is associated with
increased risk of pneumonia.[20,24,41,42] The study protocol was designed prior to data extrac-
tion by an independent steering committee and registered with the European Network of Centres
for Pharmacoepidemiology and Pharmacovigilance (ENCePP registration number ENCEPP/
EUPAS8832). Raw data were obtained from the Clinical Practice Research Datalink (CPRD), for-
merly known as the General Practice Research Database (www.cprd.com) and the UK Optimum
Patient Care Research Database (OPCRD; www.optimumpatientcare.org). The CPRD is a gov-
ernmental, not-for-profit research service, jointly funded by the NHS National Institute for
Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency, a part
of the Department of Health. All access and use of anonymised data via the CPRD are carefully
controlled under UK and European law and the rules and regulations operating in the NHS.
OPCRD has been reviewed and ethically approved by the NHS Health Research Authority to
hold and process anonymised data as part of their service delivery (Research Ethics Committee
reference: 15/EM/0150). The authors had no access to patient identifying information as part of
this study and no informed consent was necessary as the data were anonymised.
Statement of ethics approval
The study protocol was registered with the European Network of Centres for Pharmacoepide-
miology and Pharmacovigilance (ENCePP, registration number: ENCEPP/EUPAS8832). For-
mal ethics and research management approval of the study protocol was obtained from the
Anonymous Data Ethics Protocols and Transparency (ADEPT) committee and the Indepen-
dent Scientific Advisory committee (ADEPTZZ015), which verify the scientific and ethical
soundness of all research using OPCRD and CPRD data, respectively. The OPCRD has been
approved by the Trent Multi Centre Research Ethics Committee for use in clinical research.
Inclusion criteria
1. Aged: 12–80 years at the Index Prescription Date
2. Evidence of obstructive lung disease treatment defined as at least 2 prescriptions (either as
fine-particle ICS or extra-fine particle ICS) for respiratory therapy at baseline (for patients
in the ICS step-up cohort, including at least 1 prescription for ICS)
3. Continuation of therapy, defined as2 respiratory prescriptions during the outcome year
(i.e.1 in addition to that prescribed at the Index Date)
4. Two years of continuous practice data comprising 1 year baseline data and 1 year of out-
come data (up-to-standard data for CPRD patients)
Exclusion criteria
Patients with any other chronic respiratory disease, at any time were excluded from the study.
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Outcome measures
Primary outcome. Diagnosis of pneumonia: (i) unconfirmed i.e. all unique patients with
codes for pneumonia and, (ii) confirmed by chest radiograph or resulting in hospitalisation
within one month of pneumonia diagnosis.
Secondary outcomes.
1. Exacerbation of asthma or COPD: An asthma exacerbation was defined as a course of oral corti-
costeroids (OCS), hospital admission, or emergency department attendance for asthma during
the outcome year. For patients with COPD, exacerbations were defined as an acute course of
OCS, antibiotics for a lower respiratory tract infection, or a recorded hospitalisation for COPD.
2. An acute respiratory event was defined as an occurrence of any of asthma or COPD related
hospital admission, or emergency department attendance or acute use of OCS or antibiotics
prescribed with lower respiratory consultation (consisting of the following: i) Lower respi-
ratory read codes (including Asthma, COPD and LRTI Read codes); ii) Asthma/COPD
review codes excluding any monitoring letter codes; iii) Lung function and/or asthma mon-
itoring; iv) Any additional respiratory examinations, referrals, chest x-rays or events).
Statistical analyses
Baseline characteristics of unmatched and matched patients prescribed either fine- or extra-
fine particle ICS are described using summary statistics and compared using χ2 or Mann-
Whitney U tests as appropriate.
Outcome analysis
The adjusted odds of patients being coded for pneumonia in the outcome period was compared
between unmatched and matched treatment groups using logistic and conditional logistic
regression models. The dichotomous outcome for pneumonia coding/coding with confirmation
was used as the dependent variable with treatment and potential confounding factors as explan-
atory variables (diabetes, baseline treatment and COPD). Both unadjusted and adjusted odds
ratios (OR) with their respective 95% confidence intervals (CI) are reported. Results were
adjusted for average daily ICS dose in the outcome and presented by categorised average daily
ICS dose in the outcome period, to investigate the effect of ICS dose on developing pneumonia.
For the same population, two definitions of exacerbation of obstructive lung disease
(asthma exacerbation and acute respiratory event) were used to compare respiratory outcomes
between treatment groups, as indicators of clinical effectiveness. Event rates were compared
between treatment groups using Poisson regression models. Exacerbation rates were the
dependent variable, with treatment and potential confounding factors as explanatory variables
(year of ICS step-up, acute courses of oral corticosteroids (0/1/2+) and categorised average
daily ICS dose). The adjusted rate ratios (RR) with 95% confidence intervals are reported.
All analyses were carried out using IBM SPSS Statistics (version 21; SPSS Inc, Chicago, Ill),
SAS software (version 9.3; SAS Institute Inc., Cary, NC, USA) and Microsoft Office Excel 2013
(Microsoft Corporation, Redmond, WA, USA). Statistically significant results are defined as
p<0.05 and trends as 0.05 p<0.10.
Results are reported in accordance with STROBE guidelines for reporting cohort studies.
Results
The results for unmatched groups are presented in the main paper and for matched groups in
S1 File, S1 Fig and S1–S6 Tables.
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Significant differences were observed between patients who received extra-fine versus fine-
particle ICS in the demographics and baseline characteristics, as shown in Table 1. The ICS
treatments prescribed to patients before and at step-up are shown in S1 Table in the support-
ing information. At step-up, 11952 (52%) patients were on FP; 2836 (12.3%) on BDP; 8117
(35.3%) on ef-BDP and 108 (0.4%) on ef-CIC.
Patients stepping-up their ICS therapy to extra-fine particle ICS were significantly less likely
to be coded for pneumonia (OR [95% CI] 0.60 [0.37, 0.97]; p<0.011) compared to those step-
ping-up to fine-particle ICS, having adjusted for confounders (Table 2; Fig 1).
Furthermore, patients stepping-up to extra-fine particle ICS were significantly less likely to
experience acute exacerbations (RR [95%CI] 0.91 [0.85, 0.97]); p<0.001) (Table 3) and acute
respiratory events (RR [95%CI] 0.90 [0.86, 0.94]; p<0.001) (Table 4) compared with patients
stepping-up to fine-particle ICS, having adjusted for confounders.
An analysis by average daily ICS dose suggested patients receiving daily ICS doses in excess
of 700 mcg (FP equivalent) were significantly more likely (OR [95%CI] 2.38 [1.17, 4.83]);
p<0.001) (Table 5; Fig 2) to be coded for pneumonia compared with patients prescribed lower
doses, irrespective of particle size (S1 Fig in the supporting information).
Results for analysis of 6636 uniquely matched patient pairs stepping-up to extra-fine particle
ICS compared to those stepping-up to fine-particle ICS are presented in the supporting informa-
tion. S2 Table in the supporting information shows the patient flow for matching and S3 Table
the demographics and baseline characteristics. Matched patients stepping-up to extra-fine parti-
cle ICS were significantly less likely (OR [95% CI] 0.50 [0.27, 0.93]; p = 0.028) to be coded for
pneumonia compared with patients stepping-up to fine-particle ICS, before adjusting for con-
founders. After adjusting for COPD diagnosis, significance was not maintained, although a
trend for a lower incidence of pneumonia (OR [95% CI] 0.50 [0.25, 1.01]; p = 0.054) (S4 Table in
the supporting information) was seen in matched patients stepping-up to extra-fine particle ICS.
Matched patients stepping-up to extra-fine particle ICS were also significantly less likely to
experience acute exacerbations (RR [95%CI] 0.90 [0.84, 0.97]); p<0.001) (S5 Table in the sup-
porting information) and acute respiratory events (RR [95%CI] for 0.90 [0.86, 0.95]; p<0.001)
(S6 Table in the supporting information) compared with patients stepping-up to fine-particle
ICS, having adjusted for confounders.
Discussion
Our data show that patients with obstructive lung disease using fine-particle ICS (FP or BDP)
stepping-up their ICS therapy to extra-fine particle ICS (efBDP or efCIC) are significantly less
likely to have pneumonia in unmatched patients with a trend for lower incidence in matched
patients after adjusting for COPD diagnosis. Furthermore, patients on extra-fine ICS are sig-
nificantly less likely to experience adverse respiratory outcomes compared to patients step-
ping-up to fine-particle ICS on both unmatched and matched analysis. Patients on daily ICS
doses in excess of 700 mcg (fluticasone propionate equivalent) have a significantly increased
risk of pneumonia compared with patients on lower doses, irrespective of particle size. To the
best of our knowledge, this is the first study to compare the risk of pneumonia between extra-
fine and fine-particle ICS in patients with obstructive lung disease in relation to ICS dose.
Our findings are particularly pertinent in patients with chronic airway colonisation by
pathogenic bacteria, which has been identified as a risk factor for COPD disease exacerbations.
[43] Additionally, and of interest since the largest proportion of patients had solely an asthma
diagnosis while results persisted after adjusting for COPD, our findings suggest that higher
ICS doses may be driving the higher incidence rates of pneumonia seen in patients with
obstructive airway disease, as previously observed in both asthma[9] and COPD patients.[19]
Extra-fine corticosteroids and pneumonia
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Table 1. Demographic and clinical baseline characteristics for patients with obstructive lung disease prescribed fine- versus extra-fine particle
ICS.
Demographic and clinical baseline characteristics ICS particle-size P-valuea
Patients (n = 23,013)
Fine-particle ICS
(n = 14,788)
Extra-fine particle ICS
(n = 8,225)
Demographics
Sex, female 9046 (61) 4871 (59) 0.004
Age at ICS step-up date (index date), mean (SD) 44 (17) 44 (18) 0.018
Baseline weight BMI (kg/m2), mean (SD) 28 (7) 29 (7) 0.001
Year of step-up date (index date), median (IQR) 2002 (1998, 2007) 2006 (2003, 2008) <0.001
Smokingb Non-smokers 8679 (59) 4873 (59) 0.024
Current smokers 3474 (24) 1904 (23)
Ex-smokers 2476 (17) 1392 (17)
Respiratory diagnosis None 174 (1.2) 114 (1.4) NA
Asthma/ no COPD 11516 (77.9) 7171 (87.2)
COPD/ no asthma 197 (1.3) 93 (1.1)
Asthma and
COPD
2901 (19.6) 847 (10.3)
Comorbidities and Therapy
Rhinitis diagnosis and/or therapyc 6175 (42) 2754 (34) <0.001
GERD diagnosis and/or drugsd 3827 (26) 2115 (26) 0.784
Ischaemic heart disease diagnosise 1084 (7) 433 (5) <0.001
Coding for pneumoniaf 73 (0.5) 22 (0.3) 0.010
Confirmed coding for pneumoniag 25 (0.2) 12 (0.1) 0.674
Baseline characteristics
Acute oral corticosteroid coursesh 0 8542 (58) 6008 (73) <0.001
1 3103 (21) 1420 (17)
2+ 3143 (21) 797 (10)
Antibiotics prescribed with lower respiratory
consultationi
0 9027 (61) 5440 (66) <0.001
1 3060 (21) 1667 (20)
2+ 2701 (18) 118 (14)
ICS dose at date of step-up (index date), median (IQR)j 1000 (500, 1000) 400 (200, 400) <0.001
Average ICS daily dose (μg), median (IQR)j 214 (82, 438) 110 (55, 219) <0.001
Data are n (%) unless otherwise stated. BMI: body mass index; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease;
ICS: inhaled corticosteroids; IQR: interquartile range; NA: not applicable.
aConditional logistic regression.
bMatching variable.
cRead code at any time and/or prescription for nasal spray during baseline or outcome analysis period.
dRead code and/or drugs for GERD (BNF 1.3.5) at any time.
eRead code at any time.
fPneumonia coding defined as a Read code for pneumonia, at any time.
gPneumonia coding confirmed by x-ray or hospitalization.
hAcute oral corticosteroid courses were defined as all courses that are definitely not maintenance therapy, and/or all courses where dosing instructions
suggest exacerbation treatment (e.g. 6,5,4,3,2,1 reducing, or 30μg as directed), and/or all courses with no dosing instructions, but unlikely to be
maintenance therapy with a code for asthma or a lower respiratory event, where “maintenance therapy” is defined as: daily dosing instructions of <10μg
prednisolone or prescriptions for 1mg prednisolone tablets.
iLower respiratory consultations consist of the following: a) lower respiratory Read codes (including asthma, COPD and LRTI Read codes); b) asthma/
COPD review codes excluding any monitoring letter codes; c) lung function and/or asthma monitoring; d) any additional respiratory examinations, referrals,
chest x-rays or events.
jFluticasone propionate (FP) equivalent.
https://doi.org/10.1371/journal.pone.0178112.t001
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The pathophysiological mechanisms that contribute to an increased susceptibility to pneu-
monia in patients treated with ICS are unclear. In murine models, ICS have been shown to sig-
nificantly increase alveolar macrophage efferocytosis (uptake of apoptotic cells by alveolar
macrophages), thereby reducing their ability to combat microbes, including Streptococcus
pneumoniae, the most common cause of community acquired pneumonia in patients with
COPD.[44] A recent study in a cohort of children with persistent asthma taking daily ICS
showed nearly four times greater oropharyngeal colonization with Streptococcus pneumoniae
compared to children not receiving ICS,[45] which may increase the risk of having pneumo-
coccal respiratory infections. Several studies have demonstrated an intra-class difference
between both mono-component ICS and fixed combinations of ICS/LABA with regard to the
risk of pneumonia and pneumonia related events in COPD patients.[20,22,24,41] The risk of
patients with COPD developing serious pneumonia is particularly elevated and dose related
with fluticasone use and much lower with budesonide.[11] Although there have been no stud-
ies directly comparing the effects of fluticasone and budesonide on host defence, differences
are likely related to their contrasting pharmacokinetic and pharmacodynamic properties. To
Table 2. Pneumonia diagnosis by treatment group.
Pneumonia diagnosis By treatment group Total P-valuea
Fine-particle Extra-fine particle
Yes, n (%) 73 (0.5) 22 (0.3) 95 (0.4) 0.011
No, n (%) 14715 (99.5) 8203 (99.7) 22918 (99.6)
Total, n (%) 14788 (100) 8225 (100) 23013 (100)
Odds ratio adjusted for baseline confoundersb 1.00 0.60 (0.37, 0.97)
aFisher’s exact 2-sided test.
bAdjusted for baseline diagnosis for pneumonia (Y/N), diabetes diagnosis or therapy at baseline (Y/N) and COPD diagnosis (ever) (Y/N).
https://doi.org/10.1371/journal.pone.0178112.t002
Fig 1. Probability (95% CI) of pneumonia in outcome period by treatment group.
https://doi.org/10.1371/journal.pone.0178112.g001
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prevent any confounding by differences between FP and budesonide, we therefore excluded
patients using budesonide in our current analyses.
ICS are reported to be overused in the treatment of COPD[7,46–48] contrary to current
guidelines that recommend reserving the use of ICS, in addition to a maintenance therapy
with long-acting β2-agonists (LABA) and/or a LABA and long-acting muscarinic antagonists,
for patients with severe or very severe airflow limitation and/or two or more exacerbations per
year.[2] Some studies have shown that ICS discontinuation does not lead to significant adverse
effects, such as an excess of COPD exacerbations in subjects without an asthma component to
their COPD. [49–51] Furthermore, a recent Cochrane review supports current guidelines
advocating LABA as frontline therapy for COPD, with regular ICS as an adjunct only in
patients experiencing frequent exacerbations.[52]
Similarly in patients with asthma, when low-moderate doses of ICS fail to achieve symptom
control, ICS/LABA combination therapy has been shown to improve symptom control, reduce
acute exacerbations and improve lung function.[3,4,53,54] In mild-to-moderate asthma, ICS
dose-dependent improvements in markers of control occur, but the dose-response profile is
shallow and use of higher ICS doses does not increase the efficacy of these drugs and comes at
an expense of an increase in the incidence of side effects.[54–56] Extra-fine particle ICS have a
favourable safety profile with decreased local and systemic exposure, and are associated with
improved clinical outcomes when compared to equivalent ICS doses of larger sized aerosols in
patients with asthma and COPD,[31–34,39,40]. In these patients extra-fine ICS formulations
can perhaps be used at lower doses without compromising on symptom control.
Table 3. ATS/ERS exacerbations in outcome period by treatment group.
ATS/ERS exacerbations in outcome period By treatment group
Total
P-valuea
Fine-particle Extra-fine particle
0, n (%) 10087 (68.2) 6547 (79.6) 16634 (72.3) <0.001
1, n (%) 2579 (17.4) 1099 (13.4) 3678 (16.0)
2+, n (%) 2122 (14.3) 579 (7.0) 2701 (11.7)
Total, n (%) 14788 (100) 8225 (100) 23013 (100)
Rate ratio adjusted for baseline confoundersb 1.00 0.91 (0.85, 0.97)
ATS: American Thoracic Society; ERS: European Respiratory Society.
aχ2 test.
bAdjusted for year of ICS step-up, acute courses of oral corticosteroids (0/1/2+) and average daily ICS dose (categorised).
https://doi.org/10.1371/journal.pone.0178112.t003
Table 4. Acute respiratory events in outcome period by treatment group.
Acute respiratory events in outcome By treatment group
Total
P-valuea
Fine-particle Extra-fine particle
0, n (%) 7,936 (53.7) 5,353 (65.1) 13,289 (57.7) <0.001
1, n (%) 3,357 (22.7) 1,715 (20.9) 5,072 (22)
2+, n (%) 3,495 (23.6) 1,157 (14.1) 4,652 (20.2)
Total, n (%) 14,788 (100) 8,225 (100) 23,013 (100)
Rate ratio adjusted for baseline confoundersb 1.00 0.90 (0.86, 0.94)
aχ2 test.
bAdjusted for year of ICS step-up, Charlson Comorbidity Index Score (categorised), acute courses of oral corticosteroids (0/1/2) and average daily ICS dose
(categorised).
https://doi.org/10.1371/journal.pone.0178112.t004
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Our study has strengths and limitations. This study drew on two large primary care data-
bases, the CPRD and OPCRD, allowing us to obtain a large sample of 23,013 patients with
obstructive lung disease. There was no difference in the incidence of pneumonia confirmed
radiologically or by hospitalisation between COPD and asthma patients, and there is a poten-
tial that diagnostic misclassification could have arisen from acute COPD exacerbation epi-
sodes, since the patient symptoms may have been similar to those of patients with pneumonia.
Nevertheless, as patients receiving extra-fine particle ICS had significantly fewer adverse respi-
ratory outcomes compared with fine-particle ICS, we believe that diagnostic misclassification
would not have had a substantial effect on our findings. We clubbed patients with asthma and
COPD under one umbrella term of obstructive lung disease, having recognised a priori that
the data would not be adequately powered for a subgroup analysis of the individual cohorts.
Table 5. Pneumonia diagnosis by average daily consumed ICS dose during outcome period.
Pneumonia diagnosis By average daily dose (mcg FP equivalent dose) Total P-valuea
>0–200 201–400 401–700 701+
Yes, n (%) 10 (0.2) 15 (0.2) 24 (0.4) 46 (0.8) 95 (0.4) <0.001
No, n (%) 4444 (99.8) 6471 (99.8) 6141 (99.6) 5862 (99.2) 22918 (99.6)
Total, n (%) 4454 (100) 6486 (100) 6165 (100) 5908 (100) 23013 (100)
Odds ratio adjusted for baseline confoundersb 1.00 0.92 (0.41, 2.05) 1.36 (0.64, 2.87) 2.38 (1.17, 4.83)
ICS: inhaled corticosteroids; FP: fluticasone propionate.
aχ2 test.
bAdjusted for baseline diagnosis for pneumonia (Y/N), diabetes or therapy at baseline (Y/N) and COPD diagnosis (ever) (Y/N).
https://doi.org/10.1371/journal.pone.0178112.t005
Fig 2. Probability (95% CI) of pneumonia in outcome period by average daily consumed ICS dose
during outcome period.
https://doi.org/10.1371/journal.pone.0178112.g002
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However, the different pathophysiology, inflammatory profile and response to treatment in
patients with asthma and COPD could partly explain the statistical insignificance of the pri-
mary endpoint after adjusting for COPD diagnosis as our cohort was predominantly made up
of asthmatics. “Furthermore, although we excluded patients using budesonide from the analy-
sis, an ideal comparative study would be between fine-particle and extra-fine particle flutica-
sone propionate if and when such a formulation became available”.
Moreover, the seasonal and yearly variations seen in the distribution of community
acquired pneumonia and our observation period of one-year may have been inadequate to
determine a true risk. The extent of the advantage of extra-fine particle ICS over fine-particle
ICS may have been overestimated in the unmatched analysis as the matched pairs only showed
a trend for a lower risk of pneumonia with extra-fine particle ICS after adjusting for the diag-
nosis of COPD. The main benefit of a matched cohort analysis is a probable increase in effi-
ciency and the selection of the matching variables is vital.[57] In practice, it is difficult to
establish the strength of the association between matching variables, the exposure of interest
and the outcome. In real-life situations an unmatched design is probably more representative
of the patient population and therefore less biased and more generalizable. We have therefore
reported both unmatched and matched analysis results.
In summary, we have shown important findings relevant to prescribing clinicians in the
day-to-day management of patients with obstructive lung disease, where an increased risk of
pneumonia and higher rates of adverse respiratory events are more likely with fine-particle
ICS compared to extra-fine particle ICS. The benefit-risk ratio is an important measure of
safety of drugs and the additional respiratory morbidity observed in our study with higher
doses of ICS prescribed more frequently to those on fine-particle ICS favours extra-fine parti-
cle ICS for the treatment of obstructive lung diseases, particularly at higher doses. Indeed, our
data support guideline directed management[1] that recommend patients should be main-
tained at the lowest possible dose of ICS, which can potentially be achieved more easily with
extra-fine particle ICS formulations.
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